Print Page     Close Window     

SEC Filings

10-Q
APTEVO THERAPEUTICS INC. filed this Form 10-Q on 11/13/2017
Entire Document
 

 

The following table sets forth our unaudited quarterly consolidated statement of operations data for the three and nine months ended September 30, 2016:

 

(in thousands, except per share amounts)

 

Three Months Ended

September 30,

(Restated)(1)

 

 

Nine Months Ended

September 30,

(Restated)(1)

 

Revenue

 

$

2,816

 

 

$

7,203

 

Loss from operations

 

 

(90,525

)

 

 

(121,906

)

Loss before income taxes

 

 

(91,017

)

 

 

(122,323

)

Benefit from income taxes

 

 

17,608

 

 

 

18,590

 

Net loss

 

$

(73,409

)

 

$

(103,733

)

Net loss per share - basic and diluted

 

$

(3.55

)

 

$

(4.82

)

 

(1) These amounts reflect a benefit from income taxes after giving effect to the goodwill and deferred tax liability restatement discussed above. The impairment of the Company’s IPR&D in the quarter ended September 30, 2016 resulted in a benefit from income taxes of $15.3 million related to the reversal of the associated deferred tax liability in that quarter. The Company’s interim financial statements included in Form 10-Q for the quarter ended September 30, 2016 did not reflect this benefit from income taxes or the increase in impairment of goodwill.

 

18



© Aptevo BioTherapeutics, LLC.